Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Neoadjuvant CAPOXIRI Chemotherapy in the Treatment of Resectable, Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma Protocol

NCT01760252 is registered in ClinicalTrials.gov with Beth Israel Medical Center as lead sponsor.

NCT NCT01760252
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01760252 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Neoadjuvant CAPOXIRI Chemotherapy in the Treatment of Resectable, Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma Protocol
Lead sponsor
Beth Israel Medical Center
Phase
Phase 2
Overall status
Terminated
Start date
December 31, 2011
Completion date
February 21, 2018
Enrollment
17 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic pancreatic adenocarcinoma